Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment

Annals of the Rheumatic Diseases

Volumn 75, Issue 9, 2016, Pages 1637-1644

  Rech, Juergen ^a   Hueber, Axel J ^a   Finzel, Stephanie ^a   Englbrecht, Matthias ^a   Haschka, Judith ^a,b   Manger, Bernhard ^a   Kleyer, Arnd ^a   Reiser, Michaela ^a   Cobra, Jayme Fogagnolo ^c   Figueiredo, Camille ^a,d   Tony, Hans Peter ^e   Kleinert, Stefan ^e,f   Wendler, Joerg ^f   Schuch, Florian ^f   Ronneberger, Monika ^f   Feuchtenberger, Martin ^e,g   Fleck, Martin ^h   Manger, Karin ⁱ   Ochs, Wolfgang ^j   Schmitt Haendle, Matthias ^j   Lorenz, Hanns Martin ^k,l   Nuesslein, Hubert ^m   Alten, Rieke ⁿ   Henes, Joerg ^o   Krueger, Klaus ^p   Schett, Georg ^a   more..

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b St Vincent's Hospital   (Austria)

^c Instituto Federal de Sao Paulo   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f Rheumatology Practice   (Germany)

^g Kreiskrankenhaus Burghausen   (Germany)

^h Asklepios Medical Center   (Germany)

ⁱ Rheumatology Practice   (Germany)

^j Rheumatology Practice   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l ACURA Center for Rheumatic Diseases   (Germany)

^m Rheumatology Practice   (Germany)

ⁿ Schlosspark Clinic   (Germany)

^o UNIVERSITY OF TÜBINGEN   (Germany)

^p Rheumatological Practice   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPIDERMAL GROWTH FACTOR; GLYCOPROTEIN; HYDROXYCHLOROQUINE; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LEFLUNOMIDE; LEPTIN; METHOTREXATE; PROTEIN YKL 40; RESISTIN; SALAZOSULFAPYRIDINE; SERUM AMYLOID A; STROMELYSIN; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; ANTIRHEUMATIC AGENT; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY SCORE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIBIOMARKER DISEASE ACTIVITY SCORE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84985914227     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207900     Document Type: Article

References (24)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
2. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69: 631-7.
3. Aga AB, Lie E, Uhlig T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. Ann Rheum Dis 2015;74:381-8.
4. Prince FH, Bykerk VP, Shadick NA, et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther 2012;14:R68.
5. Chatzidionysiou K, van Vollenhoven RF. When to initiate and discontinue biologic treatments for rheumatoid arthritis? J Intern Med 2011;269:614-25.
6. O'Mahony R, Richards A, Deighton C, et al. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2010;69:1823-6.
7. van den Broek M, Huizinga TW, Dijkmans BA, et al. Drug-free remission: is it already possible? Curr Opin Rheumatol 2011;23:266-72.
8. Allaart CF, Lems WF, Huizinga TW. The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol 2013;31:S14-18.
9. Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;37:1781-92.
10. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping anti-rheumatic therapy-interim results from the prospective randomized controlled RETRO study. Ann Rheum Dis 2016;75:45-51.
11. Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958-67.
12. Gandjbakhch F, Conaghan PG, Ejbjerg B, et al. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol 2011;38:2039-44.
13. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54:3761-73.
14. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
15. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
16. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
17. Curtis JR, van der Helm-vanMil AH, Knevel R, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res 2012;64:1794-803.
18. Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS ONE 2013;8:e60635.
19. Fleischmann RM, Curtis JR, Hamburger MH, et al. RA population characteristics in InFoRM, a longitudinal observational study. Ann Rheum Dis 2010;69:657.
20. Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012;71:1692-7.
21. Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389-95.
22. van der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009;60:2262-71.
23. Klarenbeek NB, van der Kooij SM, Güler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-9.
24. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009;68:914-21.